secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001213900-26-016916
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics appoints former CDC Director Dr. Robert Redfield as Senior Advisor for GX-03
--------------------------------------------------------------------------------

- Dr. Redfield appointed Senior Advisor of Health Policy and Regulatory Affairs, effective immediately.
- He will provide strategic guidance on clinical development and regulatory positioning of lead candidate GX-03.
- GX-03 is currently in Phase 2 clinical trials for dermatologic inflammatory conditions.
- Dr. Redfield served as 18th Director of the CDC (2018-2021) and led federal public health responses.
- Turn Therapeutics is a clinical-stage biotech focused on targeted inflammatory and immunology therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026016916/0001213900-26-016916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026016916/ea0277212-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-016916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer